Response to 1-deamino-8-D-arginine vasopressin in von Willebrand disease.
The synthetic agent, 1-deamino-8-D-arginine vasopressin (DDAVP), is generally regarded to be the treatment of choice for persons with type I von Willebrand disease (vWD), and may be useful in type IIA vWD as well. Several formulations of the drug are available, including a highly concentrated intranasal spray formulation which is ideal for home use. The degree of F VIII and vWF response to DDAVP varies among individuals, but is generally consistent in individual patients over time. Some have tachyphylaxis while others do not. While side effects are uncommon, DDAVP is a potent antidiuretic agent. Thus one should be aware of the possibility of hyponatremia and water intoxication if certain precautions are not observed.
Division of Hematology-Oncology, Children's Hospital of Michigan, Detroit 48201.
J M
JM
Lusher
D000281:Administration, Intranasal; D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D003894:Deamino Arginine Vasopressin / Q000009:adverse effects / Q000627:therapeutic use*; D004333:Drug Administration Routes; D004359:Drug Therapy, Combination; D006801:Humans; D007279:Injections, Subcutaneous; D013618:Tachyphylaxis / Q000502:physiology; D014842:von Willebrand Diseases / Q000188:drug therapy*
D000933:Antifibrinolytic Agents; D003894:Deamino Arginine Vasopressin